Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award
Posted on: Tuesday, 21 April 2009, 09:08 CDT
Novel device for the treatment of depression named one of 2008's top medical device innovations
(Photo: http://www.newscom.com/cgi-bin/prnh/20090421/NY02319 )
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/neuronetics/37926/
"We are pleased that our NeuroStar TMS Therapy system is a recipient of one of this year's Medical Design Excellence Awards. There are many people behind the scenes such as engineers, clinical staff, and designers who deserve this recognition. We are proud to have developed this innovative medical device to help the many people suffering with depression who are in need of a new treatment option," said Neuronetics' President and CEO,
NeuroStar TMS Therapy was cleared by the FDA in
In an open-label clinical trial, which is most like real world clinical practice, approximately one in two patients experienced significant improvement in symptoms, and one in three experienced complete symptom resolution. There were no systemic side effects, such as weight gain and sexual dysfunction. The most common adverse events related to treatment were scalp pain or discomfort at the treatment area during active treatments. NeuroStar TMS Therapy may not be effective for all patients with depression. NeuroStar TMS Therapy is currently available at over 25 treatment locations in 15 states (for details visit www.NeuroStarTMS.com).
About Neuronetics
Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in
About Depression
Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year, over 30,000 people in the U.S. commit suicide, 60 percent of which suffer from depression. The economic burden of depression in 2000 was estimated at
* NeuroStar TMS Therapy(R) is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
NeuroStar(R), NeuroStar TMS Therapy(R), and TMS Therapy(R) are registered trademarks of Neuronetics, Inc.
SOURCE Neuronetics, Inc.
Source: PR Newswire
Related Articles
- Medical Device Patient Testifies Before Senate Committee on the Medical Device Safety Act
- Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
- Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award
- Isolagen Reports Positive Results From Open Label, Phase II Study of Isolagen Therapy(TM) of the Full Face Regarding the Treatment of Wrinkles and Skin Quality Characteristics
- Isolagen, Inc. Reports Positive Top-Line Results From Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and Are Statistically Significant
- Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
- Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
- FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients With Major Depressive Disorder
- Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
- FDA Approves Cyberonics' VNS Therapy(TM) System for Treatment-Resistant Depression (TRD)
 |
 |
User Comments (0)
RSS Feeds